Clinical Trial: Phase 1 Study of ECC4703 With Sulfasalazine and Pitavastatin

U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07726368) titled 'Phase 1 Study of ECC4703 With Sulfasalazine and Pitavastatin' on July 13.

Brief Summary: Non-alcoholic fatty liver disease is a chronic, serious, life-threatening, inflammatory liver disease characterized by increased liver fat content, inflammation, and progressive fibrosis. The overall prevalence of non-alcoholic fatty liver disease is rapidly rising world-wide.

ECC4703 is a potential new treatment for non-alcoholic fatty liver disease.

The purpose of this research is to investigate the safety, tolerability and pharmacokinetics of sulfasalazine and pitavastatin when combined with ECC4703.

Study Start Date: July, 2026

Study Typ...